How did patients respond to
    treatment with XPOVIO® (selinexor)?

    In the clinical trial, 134 adults with relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL) were treated with XPOVIO 60 mg on Days 1 and 3 of every week. The FDA approval was based upon the results of this trial, and additional trials may be needed.

    Chart showing XPOVIO® response rate Chart showing XPOVIO® response rate

    Response to XPOVIO was evaluated in patients regardless of status (n=39):

    • Their age
    • The number of treatments they had taken before
    • The type of diffuse large B-cell lymphoma (DLBCL) they have
    • If their DLBCL had stopped responding to other treatments
    • If they had previously had a stem cell transplant
    XPOVIO has been shown to work when taken by itself in patients with RR DLBCL.
    Patients who responded did not need to take XPOVIO with another anti‑cancer medicine.

    How long did responses to XPOVIO last?

    Patients who responded to XPOVIO had a rapid and meaningful response.

    Chart showing overall response rate Chart showing overall response rate

    *The median duration of response (DOR) was a prespecified secondary outcome, determined by a particular statistical analysis. Limitations to this analysis for the data from this study include a small number of patients and the effect of data from patients with prolonged remission durations. Approximately half of the responders in this analysis had a DOR lasting less than 3 months.

    The analysis of DOR is presented alongside an analysis demonstrating the number of patients responding at certain timepoints (3, 6, 12 months).

    The median number is the middle point of a set of numbers, in which half the numbers are above the median and half are below.

    What is XPOVIO?

    XPOVIO® (selinexor) is a prescription medicine used:

    • in combination with dexamethasone to treat adults with multiple myeloma (MM) that has come back (relapsed) or that did not respond to previous treatment (refractory), and
      • who have received at least 4 prior therapies, and
      • whose disease did not respond (refractory) to at least 2 proteasome inhibitor medicines, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody medicine

    What is the most important information I should know about XPOVIO?

    Your healthcare provider will do blood tests before you start taking XPOVIO, and often during the first 3 months of treatment, and then as needed during treatment to monitor you for side effects. Your healthcare provider may change your dose of XPOVIO, stop your treatment for a period of time, or completely stop your treatment if you have certain side effects during treatment with XPOVIO.